Safety Profile of Methotrexate Therapy in Patients With Rheumatoid Arthritis

Syed Hassan Mustafa 1 , Tausif Ahmad 2 , Malab Balouch 3 , Farah Iqbal 4 , Talha Durrani 5

1. Rheumatology, Lady Reading Hospital, Peshawar, PAK 2. Internal Medicine, NHS Highland, Inverness, GBR 3. Neurorehabilitation Unit, Charing Cross Hospital, London, GBR 4. Health Department, District Headquarters Hospital, Abbottabad, PAK 5. Department of Medicine, Khyber Teaching Hospital, Peshawar, PAK

Corresponding author: Tausif Ahmad, drtouseef198@hotmail.com

Abstract

Objective

The objective of this study was to determine the safety profile of methotrexate (MTX) therapy in patients with rheumatoid arthritis

Study design

This was a cross-sectional observational study.

Place and duration of the study

The study took place in the Division of Rheumatology, Lady Reading Hospital Peshawar, from May 2020 to August 2021.

Methodology

A total of 411 patients with rheumatoid arthritis and receiving MTX in the dose of 10-20 mg/week for at least four months were included by consecutive sampling. All patients were followed for four months for the development of cytopenias, deranged liver function tests, renal function tests, fever, and gastrointestinal upsets. Data were recorded on a pro forma.

Results

There were 237 (57.6%) females and 174 (42.4%) males. The female to male ratio was 1.4:1. The average age of patients was 43.01 years ± 17.1 SD with a range of 18-72 years. Gastrointestinal side effects were the most common, found in 49 patients (11.9%), followed by mucocutaneous side effects in 35 patients (8.5%) and fever (34 patients, 8.3%).

Conclusion

Every one in three patients developed some adverse effect within six months of methotrexate therapy. Moreover, we conclude that gastrointestinal side effects were the most common side effects seen.

Categories: Rheumatology

Keywords: mucocutaneous, cytopenias, rheumatoid arthritis, methotrexate, side effects

Introduction

Rheumatoid arthritis (RA) is a chronic multisystem autoimmune disease with a prevalence of 0.5-1% in the general population [1–2]. The disease primarily affects the small joints of the hands, leading to joint damage, and is thus associated with high morbidity. However, the long-term prognosis of the patients has improved significantly over the past few decades primarily due to the timely diagnosis and development of disease-modifying anti-inflammatory drugs (DMARDs) [3].

Methotrexate (MTX) is the most preferred DMARD used in the management of RA since a large proportion of patients (23%-40%) improve significantly with methotrexate monotherapy due to its low cost, proven efficacy, and years of clinical experience with its use [4]. Despite the development of biological therapies and targeted synthetic therapy, MTX is still used as the first-line therapy [5]. Moreover, it is also recommended to be used along with biologics since it reduces the probability of developing autoantibodies against these new drugs [4].

As an anti-metabolic drug, methotrexate therapy is not without side effects. Though these adverse effects are less common in RA patients as compared to oncology patients due to lower doses of methotrexate...
required in RA [6], some of the most common adverse effects include liver damage, myelosuppression, gastrointestinal upsets, mucocutaneous problems, and lung fibrosis. It is due to these adverse effects that many patients discontinue their methotrexate therapy [7].

The exact pathophysiology of methotrexate-induced side effects is not known. However, the development of cytopenia, mucositis, and gastrointestinal upsets demonstrate that these adverse effects develop due to a deficiency of folic acids. However, not all side effects are due to folate deficiency. For instance, the development of lung fibrosis, liver damage, and renal impairment occurs without folate deficiency. This indicates that other mechanisms may also be involved [8].

In Pakistan, methotrexate is injudiciously prescribed to patients without following the guidelines for monitoring the development of side effects of MTX therapy. Therefore, the purpose of this study is to determine the frequency of different adverse effects of methotrexate therapy in patients with rheumatoid arthritis.

**Materials And Methods**

This descriptive study was conducted in the Division of Rheumatology, Lady Reading Hospital Peshawar, from May 2020 to August 2021. The Rheumatology Division of Lady Reading Hospital is the only rheumatology unit in the whole province of Khyber Pakhtunkhwa. A total of 411 RA patients aged 18–72 years of either gender were included in the study through consecutive sampling techniques. RA was defined based on the American College of Radiology (ACR) 2010 criteria according to which all patients having a score of 6 or more will be classified as having RA. The criteria are given in Table 1.
### TABLE 1: American College of Rheumatology (ACR) 2010 criteria

Source: [9]

RF: rheumatoid factor; ACPA: anti-citrullinated protein antibodies; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate
The inclusion criteria were all adult patients > 18 years of age, either gender, diagnosed with rheumatoid arthritis, normal baseline liver function tests, complete blood picture, renal function tests, pulmonary function tests, and serum electrolytes.

The exclusion criteria were patients with viral hepatitis, patients taking other hepatotoxic drugs, diabetic patients, obese patients with a BMI of more than 30, patients having any other liver disease, such as hemochromatosis, Wilsons disease, and autoimmune hepatitis, patients with hematological conditions, such as leukemias, aplastic anemias, thrombocytopenias, or any history of recent blood loss, and patients having any previous obstructive or restrictive lung disease.

Approval was taken from the hospital ethical committee, informed consent was taken from all RA patients and they were subjected to detailed history and complete physical examination. Thereafter, 10 ml of blood was taken from all patients and sent to the hospital lab for liver function tests (LFTs), renal function tests (RFTs), and complete blood count (CBC). After that, all patients were subjected to spirometry, and PFTs were noted. All patients were started on methotrexate 10 mg/week and folic acid 5 mg/week, making sure that no patient takes both drugs on the same day. All patients were also given tapering steroids as bridging therapy and paracetamol/tramadol for pain relief only.

All patients were followed for four months, and the dose of methotrexate was increased up to 20 mg/week depending upon the patient’s disease status. At the end of four months, all patients were again examined for the development of any complications, plus 10 cc of blood was taken and sent to the hospital lab for CBC, RFTs, and LFTs. All patients were also subjected to spirometry again at the end of four months for pulmonary function tests (PFTs). The following abnormalities were noted as significant: alanine transaminase twice the upper limit of normal is considered hepatotoxic, serum creatinine of more than 1.29 mg/dl is considered nephrotoxicity, hemoglobin less than 12 gm/dl for males and 11.5 gm/dl for females is considered anemia, white cell count of less than 4000/ul is considered leucopenia, platelets of less than 150 x 10^9 /ul are considered thrombocytopenia, first second of forced expiration (FEV1)/forced vital capacity (FVC) of less than 70% is considered a pulmonary side effect, presence of or self-reported history of oral ulcers and hair loss considered mucocutaneous involvement, presence of or self-reported history of nausea, vomiting, and diarrhea considered gastrointestinal involvement, and development of or any history of any fever.

All investigations were done in the same lab and by the same doctor blinded for the study. Similarly, all the history and examination were done by a consultant physician blinded for the study. All data were recorded on a pro forma.

Data were then analyzed by SPSS 16 (SPSS Inc., Chicago, Ill). All the categorical data was calculated as frequencies and percentages. All the numerical data were calculated as mean and standard deviation. Data were stratified by age and gender. To know the significant difference, the chi-square test was used.

**Results**

A total of 411 patients with rheumatoid arthritis were included in the study. There were 237 (57.6%) females and 174 (42.4%) males. The female to male ratio was 1.4: 1. The average age of patients was 45.01 years ± 17.1 SD with a range of 18-72 years. Average methotrexate dose was 13.6 mg/week. Overall, 152 patients (32%) developed some side effects out of which 83 patients (35%) were females while 49 were male patients (28%). See Table 2 for the demographics of the study population.
| Variables                     | Frequency  |
|-------------------------------|------------|
| Total patients                | 411 (100%) |
| Females                       | 237 (57.6%)|
| Males                         | 174 (42.4%)|
| Mean age + SD                 | 43.01 years + 17.1 |
| Youngest Patient              | 18 years   |
| Oldest Patient                | 72 years   |
| Average MTX dose              | 13.6 mg/week|
| Total patients with side effects | 132 (32%) |
| Female patients with          | 83 (35%)   |
| Male patients                 | 49 (28%)   |
| The average duration of treatment (in years) | 2.49 |
| Patients who stopped treatment | 26 (6.3 %) |

### TABLE 2: Basic demographics of the study population

Gastrointestinal side effects were the most common, found in 49 patients (11.9%). Mucocutaneous side effects were the most common, found in 35 patients (8.5%), followed by fever (34 patients, 8.3%). All other side effects are given in Table 3.

| S.NO | Methotrexate side effects | Frequency  |
|------|---------------------------|------------|
| 1.   | Gastrointestinal          | 49 (11.9%) |
| 2.   | Mucocutaneous             | 35 (8.5%)  |
| 3.   | Fever                     | 34 (8.3%)  |
| 4.   | Anemia                    | 29 (7.05%) |
| 5.   | Hepatotoxicity            | 14 (3.4%)  |
| 6.   | Thrombocytopenia          | 7 (1.7%)   |
| 7.   | Leucopenia                | 6 (1.45%)  |
| 8.   | Pancytopenia              | 5 (1.21%)  |
| 9.   | Others                    | 11 (2.6%)  |

### TABLE 3: Different side effects of methotrexate

As regards gender, 34 female patients were found to develop gastrointestinal side effects compared to 15 male patients, the difference being statistically significant (p=0.04), while mucocutaneous side effects and fever were found in 17 and 16 female patients and each in 18 male patients, respectively (p=0.28). The rest of the adverse effects are shown in Table 4.
TABLE 4: Stratification of methotrexate side effects according to gender

| Methotrexate side effects | Male       | Female     | Total | p-value |
|---------------------------|------------|------------|-------|---------|
| Gastrointestinal          | 15 (30.6%) | 34 (69.4%) | 49    | 0.04*   |
| Mucocutaneous             | 18 (51.4%) | 17 (48.6%) | 35    | 0.28    |
| Fever                     | 18 (53%)   | 16 (47%)   | 34    | 0.2     |
| Anemia                    | 14 (48.2%) | 15 (51.8%) | 29    | 0.56    |
| Hepatotoxicity            | 5 (35.7%)  | 9 (64.2%)  | 14    | 0.78    |
| Thrombocytopenia          | 3 (42.8%)  | 4 (57.2%)  | 7     | 1       |
| Leucopenia                | 2 (33.3%)  | 4 (66.7%)  | 6     | 1       |
| Others                    | 4 (36.4%)  | 7 (63.6%)  | 11    | 0.76    |

TABLE 5: Chi-square test: adverse effects and treatment cessation

| Adverse effects | Yes  | No  | Total | p-value |
|-----------------|------|-----|-------|---------|
| Patients who stopped treatment |       |     |       |         |
| Yes             | 17 (4.13) | 9 (2.18%) | 26 (6.32%) |       |
| No              | 115 (27.98%) | 270 (65.69%) | 385 (93.67%) | 0.001 |
| Total           | 132 (32.11%) | 279 (67.88%) | 411 (100%) |       |

Discussion

In this study, we observed that 132 (32%) of patients developed side effects from methotrexate therapy. Moreover, we observed that adverse effects of methotrexate were more common in females as compared to male patients, but the result was not statistically significant (p=0.08).

Solomon et al., in their study, followed 4,786 patients for 23 months [6]. Patients were randomized into two groups with one group on low-dose methotrexate, i.e. ranging from 10 mg - 20 mg/ week while the other group was on placebo. They found that 87% of the patients in the methotrexate arm developed adverse effects compared to 81% in the placebo arm, with a relative rate of 17%. In our study, 32% of the patients developed adverse effects. The vast difference between these two diseases is because they followed the patients for 23 months compared to our study, as we studied them for six months only. The cumulative incidence curve of Solomon et al. further acknowledges that the frequency of side effects increases with the duration of medicine. Our findings were similar to Bologna C et al., as they observed that 23% of patients stopped methotrexate treatment due to toxicity [10].

In this study, we observed that gastrointestinal upsets were most common with methotrexate therapy, accounting for 11.9% of patients. Asai S et al. also studied the effect of low vs high-dose methotrexate therapy on the GI system of patients and observed that 32% of patients on high dose developed reflux compared to 24% on low-dose therapy [11]. Moreover, we observed that gastrointestinal adverse effects were more common in females as compared to males. One reason for these differences is that they used the Gastrointestinal Symptom Rating Scale (GSRS) while we relied on self-reporting. In their study, Atsumi et al. reported that GI adverse effects occurred in 24% of patients on methotrexate therapy [12]. The GI adverse effects that they reported were nausea, vomiting, and reduced appetite, which were the same symptoms we looked for. However, since they followed the patients for 52 weeks, they reported a higher frequency. Solomon et al., on the other hand, reported 11.4% of GI-related adverse effects, which were similar to our findings [6]. Nanke Y et al. observed that bacterial infection of the gastrointestinal tract can occur in patients on methotrexate, which can be life-threatening [13].
The mucocutaneous adverse effects of methotrexate were found in 8.5% of the patients in our study and their occurrence was irrespective of gender. Atsumi et al. reported a 16.6% frequency of patients who developed stomatitis [12]. In another study, 13.5% were found to develop mucocutaneous adverse effects [14]. Carpenter EH et al. reported that 2% of the patients stopped their methotrexate treatment due to mucositis [15]. In our study, mucositis was never severe enough to lead to treatment discontinuation. In agreement with our study, Hoekstra et al. also observed that the mucocutaneous adverse effects of methotrexate therapy do not correlate with gender [16].

Owing to the immunosuppressive activity of methotrexate, infections have always been a concern with MTX treatment. We observed that 8.3% of patients developed a fever while on methotrexate therapy. In our study, pancytopenia was reported in five patients while six patients developed leukopenia. This is in accordance with several studies that reported an increased risk of infections in rheumatoid arthritis patients on methotrexate [17-21]. In the literature, neutropenia and pancytopenia have been reported to occur in 1.4% to 7% and 0.3% to 2.1% of the patients, respectively, which is also in accordance with our study [22-26].

We reported that hepatotoxicity following methotrexate therapy in RA patients occurred in 3.4% of patients. This is in contrast to another study, which reported a 15% elevation in alanine transaminase twice the upper level of normal in patients with methotrexate therapy [27]. They also observed that the frequency of hepatotoxicity is affected by the length of therapy, with more patients developing deranged liver functions following more than one year of therapy. Moreover, additional therapies were used, which led to a higher frequency of liver damage compared to our study. In yet another study, the incidence of developing transaminases above two times the upper limit of normal was found in only 1% of patients, which is similar to our study [28].

Methotrexate-related side effects can be minimized by the concomitant use of oral folic acid [29]. In this study, patients were on oral folic acid 5 mg/week, and the dose was given 24 hrs after the methotrexate dose. Moreover, studies have also supported the use of 5 - 10 mg of folic acid per week to be used with methotrexate therapy since it reduces methotrexate toxicity [30].

So far, little data is available regarding the frequency of different adverse effects of methotrexate in the Pakistani population. Moreover, the drug is often inappropriately prescribed by physicians without following any international guidelines. In Pakistan, this problem could partially be attributed to the handling of rheumatology patients by general physicians, in contrast to specialized rheumatologists, which are lacking in the country. Another contributing factor could be the physician’s intent to get a strong and quick therapeutic response. However, neither of these causes justify the excessive use of the drug in the population. Furthermore, contrary to some of the published literature showing that the adverse effects of the drug are mild and manageable, our study showed that many patients were bothered enough by these problems that they had to switch treatments. Hence, our findings, therefore, guide the health care officials and caregivers regarding what side effects to look for in patients on methotrexate therapy.

This study has certain limitations, which include the relatively small sample size, being a unicenter study, having a short follow-up period, and a lack of randomization.

Conclusions

We conclude that every one in three patients develops some adverse effect within six months of methotrexate therapy. However, most of them are not life-threatening, and gastrointestinal side effects were the most common side effects seen. It is worth mentioning that despite methotrexate being a preferred and cost-effective option for treating rheumatoid arthritis, every patient on methotrexate therapy should be monitored for the development of side effects during every follow-up visit.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Dr Rehana Rahim, Lady Reading Hospital Medical Teaching Institution Peshawar, Ethical Review Board issued approval Reference Number: 50/LRH/MTI. Ethical approval has been obtained from Lady Reading Hospital Medical Teaching Institution Peshawar, Ethical Review Board (Approval Reference number is 50/LRH/MTI ). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
References

1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018, 6:15. 10.1038/s41414-018-0016-9

2. Abhishek A, Doherty M, Kao CF, Mallen CD, Zhang W, Grainge MJ: Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study. Rheumatology (Oxford). 2017, 56:736–44. 10.1093/rheumatology/kew448

3. Lappentin K, Ebsenham BA, Østergaard M, Ibsen R, Kjellberg J, Jenum P: Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: a nationwide register study. J Comorb. 2019, 9:2235042X19853484. 10.1177/2235042X19853484

4. Taylor PC, Balsa Criaò A, Mongey AB, Avouej J, Marotte H, Mueller RB: How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?—MTX in the treat-to-target strategy. J Clin Med. 2019, 8:515. 10.3390/jcm8040515

5. Pajden I, Crmogi MR, Anić B: Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. Reumatologija. 2020, 58:590–400. 10.5114/reum.2020.101400

6. Solomon DH, Glynn RJ, Karlson EW, et al.: Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020, 172:569–80. 10.7326/M19-3369

7. Romão VC, Lima A, Bernardes M, Canhão H, Fonseca JE: Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?. Immunol Res. 2014, 60:289–310. 10.1007/s12026-014-8564-6

8. Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007, 65:168–73.

9. Aletaha D, Neogi T, Silman AJ, et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569–81. 10.1002/art.27584

10. Bologna C, Viu P, Picot MC, Jorgensen C, Sany J: Long-term follow-up of 455 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol. 1997, 36:535–40. 10.1093/rheumatology/36.5.535

11. Asai S, Nagai K, Takahashi N, et al.: Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis. 2019, 22:207–15. 10.1111/1756-185X.13580

12. Atsumi T, Yamamoto K, Takeuchi T, et al.: The first double-blind, randomised, parallel-group, placebo-controlled pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016, 75:75–83. 10.1136/annrheumdis-2015-207511

13. Nanke Y, Kotake S, Akama H, Tomii M, Kamatani N: Paracyclopemia and colitis with Clostridium difficile in a rheumatoid arthritis patient taking methotrexate, antibiotics and non-steroidal anti-inflammatory drugs. Clin Rheumatol. 2001, 20:75–82. 10.1007/p100011187

14. Conaghan PG, Østergaard M, Bowes MA, et al.: Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naïve, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016, 75:1024–33. 10.1136/annrheumdis-2015-208267

15. Carpenter EH, Plant MJ, Hassell AB, et al.: Management of oral complications of disease-modifying drugs in rheumatoid arthritis. Br J Rheumatol. 1997, 36:473–8. 10.1093/rheumatology/36.4.473

16. Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijen MW, Laan RF: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 62:423–6. 10.1136/ard.2004.028332

17. van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW: Injection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994, 53:224–8. 10.1136/ard.53.4.224

18. Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007, 46:1157–60. 10.1093/rheumatology/ken076

19. Coyne P, Hamilton J, Heycock C, Saravanavan V, Coulson E, Kelly CA: Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol. 2007, 34:1832–36.

20. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA: The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008, 35:897–905.

21. Saha M, Shipley D, McBride S, Kennedy C, Vega-Lopez F: Atypical cutaneous leishmaniasis in two patients receiving low-dose methotrexate. Br J Dermatol. 2006, 155:830–5. 10.1111/j.1365-2133.2006.07418.x

22. Buchbinder R, Hall S, Sambrook PN, et al.: Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1995, 20:639–44.

23. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF: The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005, 44:61–6. 10.1093/rheumatology/keh512

24. Grove ML, Hassell AB, Hay EM, Shadforth MF: Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM. 2001, 94:509–19. 10.1093/qjmed/94.6.509

25. Lim AY, Gaffney K, Scott DG: Methotrexate-induced paracyclopemia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005, 44:1051–5. 10.1093/rheumatology/keh685

26. Uusitalo ST, Khan DA, Khan FA, Ahmed M: Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012, 22:101–4.

27. Salliot C, van der Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009, 68:1100–4. 10.1136/ard.2008.093690

28. Dirven L, Klarenbeek NB, van den Broek M, et al.: Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clin Rheumatol. 2013,
29. Dhir V, Sandhu A, Kaur J, et al.: Comparison of two different folic acid doses with methotrexate—a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015, 17:156.

50. Shea B, Swinden MV, Ghogomu ET, et al.: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014, 41:1049-60. 10.5899/jrheum.130738